Evidence map›Paper›PMID 40853113›Full record

ArticleJournal of clinical microbiology2025

Paradoxical carbapenemase activity detected by modified carbapenemase inactivation (mCIM) method in

D Garrett Brown, Matthew Surette, Sreejana Ray, Kevin Guo, Reagan Chan, Liusheng Huang, Sanchita Das

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Investigation of carbapenem-hydrolysingJournal of medical microbiology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

D Garrett Brown *Department of Laboratory Medicine, National Institutes of Health (NIH), Bethesda, Maryland, USA.ORCID 0000-0001-8779-7048
Matthew Surette *Department of Laboratory Medicine, National Institutes of Health (NIH), Bethesda, Maryland, USA.
Sreejana RayDepartment of Laboratory Medicine, National Institutes of Health (NIH), Bethesda, Maryland, USA.ORCID 0000-0002-1955-1131
Kevin GuoDepartment of Clinical Pharmacy, University of California San Francisco, San Francisco, California, USA.
Reagan ChanDepartment of Clinical Pharmacy, University of California San Francisco, San Francisco, California, USA.
Liusheng HuangDepartment of Clinical Pharmacy, University of California San Francisco, San Francisco, California, USA.ORCID 0000-0003-2702-4486
Sanchita DasDepartment of Laboratory Medicine, National Institutes of Health (NIH), Bethesda, Maryland, USA.ORCID 0000-0002-2246-7942

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Screening for carbapenemase-producing Enterobacterales is a necessity for hospitals serving high-risk patient populations. Detection methods often incorporate the modified carbapenemase inactivation method (mCIM) test to verify carbapenemase production in suspect isolates. Here, we demonstrate the case of a

Indexed as

Bacterial Proteinsbeta-LactamasesCitrobacterAnti-Bacterial AgentsCarbapenemsEnterobacteriaceae InfectionsHumansMeropenemMicrobial Sensitivity TestsWhole Genome SequencingAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasescarbapenemaseCarbapenemsMeropenemantimicrobial resistance testingCitrobacter sedlakiifalse-positive mCIM

Identifiers

PMID40853113
PMCPMC12506007

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.